Who should not take Tesamorelin?
Documented caution flags for Tesamorelin include active malignancy and pituitary disorders. This is not exhaustive, and absence from this list is not a safety clearance. Anyone pregnant, nursing, or managing a serious medical condition should only consider it under a doctor's care, and safety data for Tesamorelin is limited.
Documented caution flags for Tesamorelin
- Active malignancy
- Pituitary disorders
- Pregnancy / nursing
Reported side effects to weigh
- Injection-site reaction
- Fluid retention
- Joint stiffness
- Numb/tingling extremities
References
- Tesamorelin for HIV-associated lipodystrophy — Falutz J et al., NEJM, 2007
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial — Stanley TL et al., JAMA, 2014
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data — Falutz J et al., Journal of Clinical Endocrinology & Metabolism, 2010
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Tesamorelin
Full Tesamorelin breakdownTesamorelin what it's used forTesamorelin side effectsTesamorelin how to take itTesamorelin mistakes to avoidTesamorelin half-lifeTesamorelin how long to workTesamorelin legal statusTesamorelin how it workscjc 1295 vs tesamorelinaod 9604 vs tesamorelinipamorelin vs tesamorelintesamorelin vs sermorelinAsk the AI Coach
Last updated 2026-06-15.